The apolipoprotein E (APOE) 4 allele is a genetic risk factor for the development of late-onset Alzheimer's disease (AD), which affects cholinergic system functioning. The association between reduced cholinergic levels and increase of magnetoencephalographic (MEG) low-frequency has been used to explain spectral changes found in AD patients. However, the investigation in predementia stages is scarce. We obtained MEG recordings from 25 aged controls and 36 mild cognitive impairment (MCI) patients during a resting-state condition. According to their APOE genotype, MCIs and controls were subdivided in carriers and non-carriers of the 4 allele. Sources of spectral variations in these groups were calculated through beamforming. MCI patients exhibited a significant increase of relative power within the low-frequency domain, accompanied by a power decrease within the high-frequency range. APOE4 carriers showed an increased relative power in the 4.5-6.5 Hz frequency range over frontal lobes. The power increase observed in controls carrying 4 was significantly higher as compared * Correspondence to: Alberto Fernández, PhD, Department of with MCI non-carriers, while MCI carriers exhibited the highest relative power within the 4.5-6.5 Hz range. Higher power values within the low-frequency ranges correlated with a poorer cognitive performance in MCIs and controls. Our investigation demonstrates that APOE4 affects resting-state activity to an extent that makes it more proximate to the pattern observed in early stages of AD. Therefore, a combination of genetic and neurophysiological information might help to detect MCI patients at higher risk of conversion to AD, and asymptomatic subjects at higher risk of developing a manifest cognitive deterioration.
INTRODUCTION
The human apolipoprotein E (APOE) 4 allele is the most established genetic risk factor for the development of late-onset Alzheimer's disease (AD) [1] [2] [3] . APOE is a lipid-binding protein which is expressed in humans as three alleles, designated 2, 3, and 4 [4] . Although APOE4 is neither necessary nor sufficient to cause by itself the late-onset variant [5, 6] , the risk of suffering from AD is increased for all genotypes containing the 4 allele [7] . Several investigations tried to unveil the physiological process that underlies the relationship between APOE4 and higher risk of developing late-onset AD. For instance, postmortem analyses revealed a significant correlation between the presence of an APOE4 allele and a higher amyloid-␤ (A␤) burden in AD patients' brains. This indicates that APOE may interact with A␤ by enhancing its deposit in form of plaques [8, 9] . The proliferation of A␤ deposits associated with APOE4 was further supported by recent biomarker investigations [10, 11] . Additionally, some studies demonstrated that APOE regulates the effects of growth factors and oxidative processes. The APOE3 allele promotes greater neurite outgrowth and higher neural prevention from the oxidative stress in comparison to APOE4 [12] . What is more, APOE has been associated with the modulation of neurotransmitter release in the glutamatergic system, thus preventing excitotoxicity [13] . Animal models showed that APOE-deficient specimens exhibit decreased synaptic density in the septohippocampal and nucleus-basalis cholinergic pathways due to a so-called "pre-synaptic derangement" [14] .
The influence of APOE on cholinergic neurotransmission is of particular importance, because nucleus-basalis projections to the cortex are believed to modulate the oscillatory neural activity reflected by modifications of the electroencephalographic (EEG) and magnetoencephalographic (MEG) spectrum [15] . Riekkinen et al. found a strong relationship among reduced cholinergic levels, increased delta power, and cognitive deterioration in AD [15] [16] [17] . Lehtovirta et al. [18] hypothesized that such a relationship might explain the significant slowing of the EEG spectrum in AD patients carrying the 4 allele, in comparison to non-carriers. If this notion is assumed, similar results might be expected in earlier stages of the degenerative process (i.e., mild cognitive impairment, MCI) or even in asymptomatic subjects carrying the 4 allele. Babiloni et al. [19] performed the first EEG investigation on APOE4 including a sample of MCI patients. However, the genetic information of aged controls was not available, thus preventing a broader interpretation of 4 effects on brain oscillations.
Considering the need of a more comprehensive research within this field, the aim of this study was to explore the influence of APOE4 on the resting-state MEG activity of MCI patients and healthy controls. To the best of our knowledge, this is the first neurophysiological investigation where healthy aged controls carrying the 4 allele are compared with MCI-4 carriers and non-carriers. Following the cholinergic hypothesis, we expect that aged controls carrying the 4 allele would exhibit a pattern of slowing, which includes increased power within the low-frequency range, and reduced activity within the high-frequency range. According to previous results by Babiloni's group, MCI patients carrying the 4 allele will show a reduced power within the high-frequency bands.
MATERIALS AND METHODS

Participants
MEG signals were obtained from 61 (25 controls and 36 MCI patients) right-handed [20] , native Spanish speakers. MCI patients were recruited from the Geriatrics and Neurology Units of the "Hospital Universitario San Carlos", and the "Memory Decline Prevention Center", both in Madrid, Spain. Healthy volunteers were recruited from the "Seniors Center of Chamartin District", Madrid. 
Diagnostic criteria
All participants were screened by means of a variety of standardized diagnostic instruments that included: the Spanish version of the Mini Mental State Examination (MMSE) [21] , the Global Deterioration Scale [22] , the Functional assessment questionnaire [23] , the Yesavage's Geriatric Depression Scale [24] , the Hachinski Ischemic Score [25] , the questionnaire for Instrumental Activities of Daily Living [26] , and the Functional Assessment Staging [27] .
MCI diagnosis was established according to Grundman et al.'s [28] criteria that includes: (a) memory complaint, corroborated by an informant; (b) abnormal memory function detected in formal testing; (c) normal general cognitive function; (d) total absence or minimal impairment in activities of daily living; and (e) not demented according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria [29] . Patients and controls were free of significant medical, neurologic and/or psychiatric diseases (other than MCI) and none of them were using drugs which could affect MEG activity (including cholinesterase inhibitors).
The entire sample received an exhaustive neuropsychological assessment in order to establish their performance level in multiple cognitive domains. The neuropsychological protocol has been fully described elsewhere [30] . According to their clinical and neuropsychological profile, all MCI patients fulfilled the criteria of amnestic single-domain subtype, since they exhibited isolated memory impairment [31] . Prior to the MEG recording, all subjects signed an informed consent that explained the technical and ethical considerations of the investigation. The study was approved by the local Ethics Committee.
APOE genotype test
Genomic DNA was extracted from whole-blood samples of MCI patients and controls. APOE was determined using standard methods [32] . On the basis of such genotyping the MCI and control groups were subdivided in four genetic subgroups: 16 subjects with APOE3 4 henceforth called MCI34 group; 20 subjects with APOE3 3, henceforth called MCI33 group; 6 healthy subjects with APOE3 4, henceforth called C34 group and 19 healthy subjects with APOE3 3, henceforth called C33 group. Due to the reduced sample size (only two subjects), APOE4 4 carriers were not included in the subsequent analyses. No significant differences in terms of age distribution emerged from groups' comparison (see Table 1 for demographic and genetic description).
MEG acquisition
Three minutes of resting state with eyes closed were recorded at 1000 Hz sampling rate (online bandpass filtering at 0.1-330 Hz) with a 306-channel Vectorview system (ElektaNeuromag) which combines two orthogonal, planar gradiometers, and one magnetometer. Only magnetometers information was submitted to source and statistical analyses. The MEG system was placed in a magnetically shielded room (VacuumSchmelze GmbH, Hanua, Germany) at the "Laboratorio UPM-UCM de Neurociencia Cognitiva y Computacional" (Madrid, Spain).
The head movement was controlled by means of four head-position indicator (HPI) coils attached to the scalp. The position of HPI coils and subject's headshape relative to three anatomical locations (nasion and both preauricular points) were defined using a 3D digitizer (FastrakPolhemus). Ocular movements were monitored by two bipolar electrodes. Recordings were offline filtered and corrected for head movements with a temporal signal space separation filter (Maxfilter Software 2.2) [33] .
MRI acquisition
3D T1 weighted anatomical brain MRI scans were collected with a General Electric 1.5T MRI scanner, using a high-resolution antenna and a homogenization PURE filter (Fast Spoiled Gradient Echo) sequence with parameters: TR/TE/TI = 11.2/4.2/450 ms; flip angle 12 • ; 1 mm slice thickness, a 256×256 matrix and FOV 25 cm). 
Source analysis
Data analysis was done using both Fieldtrip software [34] and custom-made scripts.
MEG preprocessing
Magnetometers' resting state data were automatically scanned for ocular, muscle, and jump artifacts. Then artifact-free data were segmented in continuous 4-second fragments (trials) and MEG power spectra (1.5-30 Hz) were computed for all trials. An experienced technician blinded to the subjects' diagnosis made a visual inspection of these spectra. Those trials with an aberrant power spectra profile were dismissed. Finally, only MEG recordings with at least 15 clean trials (one minute of brain activity) were kept for further analyses. The number of clean trials did not differ significantly (p < 0.05) among groups. In order to calculate the source reconstruction, clean trials were filtered (1.5-30 Hz) with a Finite Impulse Response filter of order 1000 using the whole three-minute register to avoid edge effects.
Headmodels
Firstly, a regular grid of 302 nodes with 2 cm spacing was created in the template Montreal Neurological Institute (MNI) brain. This set of nodes was transformed to subject's space using a nonlinear normalization between the native T1 image (whose coordinate system was previously transformed to match the MEG coordinate system) and a standard T1 in MNI space with 2 mm resolution. This grid constituted the source locations. The forward model was solved with the realistic single-shell model introduced by Nolte [35] .
Beamforming
Source reconstruction was performed with a Linearly Constrained Minimum Variance beamformer [36] . For each subject, the covariance matrix was first averaged over all trials to compute the spatial filter's coefficients, and then these coefficients were applied to individual trials, obtaining a time series per segment and source location.
Power spectra
MEG power spectra were computed at each node for all non-artifacted trials. A frequency-of-interest range of 0.5 Hz steps from 1.5 to 30 Hz was employed. In order to obtain the average frequency-content of each trial we applied a multitaper method (mtmfft) with discrete prolate spheroidal sequences (dpss) as windowing function and 1 Hz smoothing. Trials were averaged across subjects, obtaining a matrix with dimension: 302 nodes × 58 frequency steps × 61 subjects. For each node the relative power was calculated by normalizing with the total power over the 1-30 Hz range [37] .
Atlas based analysis
For the subsequent analysis, we selected 30 regions of interest (ROIs) including relevant regions in the resting state networks literature and A␤ deposition: cingulate cortex, precuneus, hippocampus, occipital cortex, parietal cortex, temporal cortex, and prefrontal cortex [38] [39] [40] [41] . Anatomical labels were assigned to each of the 302 nodes with the Harvard-Oxford probabilistic atlas [42] . In order to obtain a balance between specificity and reliability, all ROIs used in this study had to have at least two nodes within them. In addition, each node had to have a minimum 15% of probability to belong to the corresponding ROI and was assigned to the ROI which had higher probability to belong to (see Tables 2a, b) . Finally, power values were averaged per ROIs and the original 302 × 58 × 61 matrices were transformed into 30 × 58 × 61 matrices.
Statistics
Similarly to previous works [30, 43] , we accomplished a data-driven comparison among groups that did not use pre-established and conventional frequency bands. Thereby, we followed a method adapted from Maris and Oostenveld [44] . Firstly, values were transformed with x = log x 1 − x to obtain a normal distribution. Secondly, to examine power differences due to APOE genotype and diagnosis, power values were subjected to an exploratory two-way ANOVA test per each frequency step, which includes "Diagnosis" and "Genotype" as factors. In order to perform such analyses, a criterion of frequency adjacency was applied by considering significant ROIs to those whose differences remain significant during at least a 2 Hz-interval. Relative power on each significant ROI was averaged across the corresponding frequency range and inspected by means of pairwise t-tests. Post hoc pairwise comparisons involved the analysis of main and interaction effects (Diagnosis and Genotype). The relationship between power values and neuropsychological performance was assessed through Pearson correlation tests in the whole sample (MCIs + Controls). The analyses were performed by correlating the average power of each significant ROI within the corresponding frequency ranges and the scores on each neuropsychological test. To control the family-wise error due to multiple comparisons, a permutation test procedure was utilized [45] for ttests and correlations. This procedure has been fully described elsewhere [30] . Moreover, all t-test comparisons involving the C34 group underwent an additional correction due to the limited number of subjects in this group. Ten subjects from the other groups were randomly selected and a new t-test was performed. This procedure was repeated 2000 times and only results that remained significant in the 85% of the tests were reported. Finally, the effect sizes were calculated through the following expression:
. The symbol σ was the standard deviation of the control group (all controls in the case of diagnosis main effect results, and all the APOE3 population in the case of the APOE genotype main effect).
RESULTS
Diagnosis effects
The MCI group showed a significant power increase within a 6-9 Hz frequency range as compared with healthy controls (see Fig. 1 ) in 29 of the 30 ROIs. Only the superior frontal gyrus (SFG) did not show that effect. Within the alpha range (10-14 Hz) the right frontal orbital cortex (rFOC) and left temporal pole (lTP) showed a significant decrease in relative power in MCI group when compared with healthy controls (see Fig. 2 ). As it can be observed in Fig. 2 , relative power values in both regions exhibited a progressive decrease, with C33 group showing the highest values and MCI34 group showing the lowest values. Finally, within beta range (19-22 Hz) Diagnosis exerted a significant effect on four ROIs: left angular gyrus (lAng), left lateral inferior occipital cortex (lLIOC), right LIOC (rLIOC), and occipital pole (OP). All of them showed a decrease in the relative power within MCI group as compared with healthy controls (see Fig. 3 ).
Genotype effects
APOE Genotype exerted a significant effect on SFG power values. Overall, APOE3 4 carriers exhibited a significantly increased relative power within a "low" theta range (4.5-6.5 Hz) when compared with APOE3 3 carriers (see Fig. 4 ). APOE3 4 carriers showed higher power values both within MCI and control groups. Thereby, the comparison between MCI34 versus MCI33, and C34 versus C33 was significant in both cases. Of note, the distribution of power values across groups suggested a combined influence of Genotype and Diagnosis effects. C34 subjects exhibited significantly higher relative power within the 4.5-6.5 Hz frequency range when compared with MCI33 patients, while MCI34 patients showed the highest power values within this particular range. Importantly, no significant differences emerged from the comparison of MCI33 and C33 groups.
Power-neuropsychology correlation 4.5-6.5 Hz frequency range
This frequency range emerged as significant in the analysis of genotype effects. SFG power values correlated negatively with MMSE scores, indicating that an increased relative power within this region is associated with a more important cognitive decline (see Table 3 ).
6-9 Hz frequency range
As it was previously described, the significant increase of relative power within this frequency range in MCIs almost comprises all anatomical regions. Such a "massive" effect correlated inversely with MMSE, Immediate and Delayed Recall, Boston Naming Test, Trail Making Test (TMT)-B accuracy, and Inverse Digit Span. On the other hand, there were positive correlations between relative power values on most of the ROIs and TMT-B time. Finally, there existed a slight direct correlation between power in both SMGs, lSTG, and TMT-A Time scores. These results indicate that higher relative power values in these ROIs are associated with lower cognitive status in different domains (see Tables 4a-c) .
10-14 Hz frequency range
Relative power values within this frequency range in rFOC and lTP were positively correlated with MMSE, Immediate and Delayed Recall. Accordingly, the higher the relative power in these ROIs the better the global cognitive status and the performance in memory scores (see Table 5 ).
19-22 Hz frequency range
OP, lAng, lLIOC, and rLIOC power values were positively correlated with MMSE, Immediate and Delayed Recall, TMT-B Accuracy, Boston Naming Test, and Inverse Digit Span. TMT-B Time was inversely correlated with power values in the four ROIs. TMT-A Time The horizontal bars on top indicate the significant power differences (p < 0.05) due to APOE main effect and pairwise t-test comparisons among groups. The effects size for the relative power comparison between 4 carriers and non-carriers in SFG is 1. 41. followed the same tendency but only with lAng and lLIOC ROIs. So, mirroring the 10-14 Hz frequency range, increased high-frequency values are associated with a better cognitive performance (see Table 5 ).
DISCUSSION
The results presented in this report add further information on the influence of APOE genotype in the resting-state neurophysiological activity of MCI patients and healthy aged controls. As expected, MCI patients exhibited a significant increase in relative power within the low-frequency domain, accompanied by a power decrease within the alpha and "high" beta frequency ranges. More importantly, APOE3 4 carriers showed a significant increase in relative power within a 4.5-6.5 Hz frequency range in the SFG. This increase appeared in MCIs and healthy controls, indicating that the presence of an 4 allele produces a pattern of "slowing" of the MEG background activity. This slowing was prominent enough to cause a significant increase of relative power within the C34 group as compared with the C33 group but also with the MCI33 group. In addition, the MCI34 patients exhibited the highest relative power within the 4.5-6.5 Hz range. Contrary to our prediction based on previous studies, no differences emerged within the high-frequency range related to APOE effects. Finally, higher power values within the low-frequency ranges were associated with a poorer cognitive performance in MCIs and controls, and increased power within higher frequency ranges were associated with a better cognitive status. The pattern of slowing observed in MEG activity of MCI patients has been seen in several neurophysiological investigations (see, [46] [47] [48] [49] ). In a recent study, López et al. [30] reported in a sensor-domain study that MCI patients showed a generalized increase of theta activity. This was accompanied by a decrease in the alpha and beta frequency ranges that was localized in occipital, temporo-parietal, and frontal regions. The importance of alpha activity sources that extend beyond the traditional posterior sites in MCI patients has also been stressed in source-domain investigations [50] . With respect to the correlation analyses, our results support previous studies [51] [52] [53] . The MCI group showed higher power values within the 6-9 Hz frequency range in a large number of brain regions, including both hippocampi. This increase was related to lower performance in several cognitive functions such as executive functioning, memory or language. In addition, the decreased power within high frequency ranges was directly correlated with the performance in neuropsychological tests and functional status. For instance, within 10-14 Hz range, lower activity in frontal and temporal areas leads to a poorer performance in the episodic memory tests (i.e., Immediate and Delayed Recall) and cognitive functioning (i.e., MMSE). With regards to APOE effects, Lehtovirta et al. [18] reported that AD patients showed higher theta and lower beta amplitude, with 4 carriers showing an "extra" slowing. After a follow-up period of three years, differences between AD-4 carriers and non-Regarding to APOE influence on white matter, Honea et al. [63] demonstrated that APOE4-positive non-demented subjects had lower fractional anisotropy values. These values correlated with a poorer cognitive performance and hippocampal atrophy. Mirroring these results, Bagepally et al. [64] found lower fractional anisotropy scores in AD patients and healthy aged controls carrying APOE4. Importantly, the reduction of white matter integrity in 4 carriers might be explained by a possible major role of APOE in myelin sheath building [65] . Such a role is of particular importance because white matter participates in the speed control of impulse conduction, and as a consequence in the synchronization among cortical regions [66] . Synchronization among brain regions is a basic mechanism that explains the frequencies' variability observed in EEG/MEG signals [67] .
Fractional anisotropy studies of APOE and our own results share a common finding: asymptomatic controls seem to exhibit some kind of change in their physiological response which apparently is not associated with any overt clinical manifestation. Similarly, FDG-PET studies of young and middle-aged APOE4 carriers [68] [69] [70] [71] consistently found a pattern of hypometabolism in some regions such as the precuneus, posterior cingulate, and posterior parietal areas that are considered key structures in AD. Even more intriguing results were found in recent investigations of cerebrospinal fluid, PET-PIB, and PET-florbetapir imaging in aged asymptomatic 4 carriers [11, 72, 73] . Overall, these studies revealed that asymptomatic 4 carriers have significant A␤ deposition in their brains. In some cases [72, 73] , the levels of deposition may be even higher than in ADs that do not carry the 4 allele. Mirroring these findings, our C34 sample presented a more pronounced slowing of their MEG background activity than diagnosed MCI patients. This is traditionally associated with cognitive deterioration [74, 75] . Such association is supported by the significant negative correlation between frontal power within the 4.5-6.5 frequency range and MMSE scores. This suggests that the presence of the 4 allele does not have a negative influence on specific cognitive areas. On the other hand, it does negatively affect the global cognitive ability, which seems to highlight its involvement in the earlier onset of the dementia.
Our investigation demonstrates that APOE4 affects normal resting-state activity in MCI patients and controls, to such an extent that it makes it more proximate to the typical pattern observed in the early stages of AD. Taking this into account, a combination of genetic and neurophysiological information might help to detect MCI patients at higher risk of conversion to AD (see for example [76] ), and asymptomatic subjects at higher risk of developing a manifest cognitive deterioration. Notwithstanding, the results obtained in our research should be treated with caution as they have some limitations. First of all, our sample size is relatively small and this problem affects C34 group to a greater extent. As we described in the Statistics section, all comparisons where this group was involved were treated with a very restrictive strategy in order to avoid the appearance of Type I errors. Unfortunately, we cannot state with complete confidence that Type II errors were totally avoided, and some significant differences might have been missed (i.e., APOE effects on high-frequency ranges). On the other hand, MCIs and controls were not followed-up for this particular investigation, and information about a potential progression was not yet available. Nevertheless, we believe that this research offers valuable knowledge about the interaction of neurophysiological and genetic variables in aging and cognitive deterioration. Authors' disclosures available online (http://www.jalz.com/disclosures/view.php?id=2374).
